background
overexpress
colorect
cancer
crc
render
tumour
cell
resist
apoptosi
select
inhibit
effect
crc
prevent
although
advers
cardiovascular
effect
thu
focu
shift
downstream
pathway
method
microarray
experi
identifi
gene
regul
crc
cell
vitro
vivo
regul
dap
kinaserel
apoptosisinduc
kinas
apoptosisinduc
kinas
valid
qrtpcr
result
inhibit
induc
apoptosi
enhanc
express
cell
increas
h
qrtpcr
p
effect
prevent
coadministr
pge
level
suppress
panel
human
colorect
tumour
n
compar
normal
mucosa
show
invers
correl
express
r
r
p
administr
select
inhibitor
rofecoxib
patient
crc
n
induc
express
tumour
increas
p
vitro
silenc
rnai
enhanc
crc
cell
surviv
follow
inhibitor
treatment
conclus
serin
threonin
kinas
implic
regul
apoptosi
neg
regul
vitro
vivo
suggest
novel
mechan
effect
cancer
cell
surviv
colorect
cancer
crc
remain
lead
caus
cancer
death
worldwid
one
million
new
case
year
mani
half
million
cancer
death
annual
boyl
leon
express
increas
major
colorect
tumour
eberhart
et
al
induct
associ
advanc
tumour
stage
correl
poor
clinic
outcom
sheehan
et
al
nonsteroid
antiinflammatori
drug
nsaid
inhibit
cox
activ
show
antineoplast
effect
vitro
richter
et
al
sheng
et
al
human
studi
demonstr
use
associ
reduc
incid
colorect
neoplasia
sandler
et
al
although
recent
studi
confirm
chemoprevent
activ
nsaid
arber
et
al
baron
et
al
bertagnolli
et
al
also
clear
longterm
use
associ
unaccept
increas
risk
cardiovascular
event
bertagnolli
et
al
bresali
et
al
antineoplast
properti
agent
result
inhibit
prostaglandin
gener
particularli
prostaglandin
e
pge
abund
vivo
product
activ
crc
cell
pugh
thoma
riga
et
al
although
appear
pge
modul
variou
process
fundament
tumour
cell
surviv
alter
prolifer
suscept
apoptosi
sheng
et
al
sheng
et
al
sheng
et
al
tang
et
al
precis
molecular
mechan
remain
unclear
strong
rational
exist
therefor
gener
complet
understand
downstream
target
activ
doherti
murray
may
lead
develop
refin
therapi
sideeffect
profil
allow
generalis
use
previou
studi
examin
gene
regul
crc
cell
focus
long
time
point
use
rel
high
dose
nsaid
zhang
duboi
mind
set
explor
earli
chang
gene
express
crc
cell
result
lowdos
treatment
select
inhibitor
improv
understand
earli
signal
event
downstream
prostaglandin
product
one
candid
gene
identifi
dap
kinaserel
apoptosisinduc
kinas
one
famili
serin
threonin
kinas
share
abil
induc
apoptosi
sanjo
et
al
aim
studi
explor
relationship
potenti
downstream
regul
cell
surviv
crc
cell
grown
cultur
humidifi
co
incub
cell
kindli
donat
susan
kirkland
icrf
london
uk
cell
cultur
dmem
fb
supplement
mm
sodium
pyruv
mg
ml
kanamycin
approxim
confluenc
treatment
cell
purchas
atcc
rockvil
md
usa
maintain
mccoy
medium
contain
mm
lglutamin
fb
penicillin
u
ml
streptomycin
mg
ml
select
inhibitor
gift
dr
peter
isakson
searl
skoki
il
usa
pge
purchas
cayman
st
loui
mo
usa
staurosporin
purchas
calbiochem
san
diego
ca
usa
valid
sirna
target
sequenc
exon
gene
purchas
ambion
inc
austin
tx
usa
sirna
scrambl
sequenc
target
scrambledneg
control
vitro
transcrib
oligonucleotid
templat
use
silenc
sirna
construct
kit
ambion
inc
vector
purchas
bd
clontech
san
jose
ca
usa
total
rna
isol
cell
tissu
follow
homogenis
rna
lysi
buffer
qiagen
gmbh
hilden
germani
supplement
bmercaptoethanol
extract
perform
use
rneasi
midi
kit
qiagen
gmbh
rna
qualiti
determin
agaros
gel
analysi
rna
concentr
determin
spectrophotometri
genequ
pro
amersham
biotech
buck
uk
total
rna
isol
outlin
cell
treat
h
mm
vehicl
cdna
synthesis
use
custom
superscript
dscdna
synthesi
kit
invitrogen
carlsbad
ca
usa
sampl
variou
time
point
pool
underw
vitro
transcript
use
enzo
ivt
kit
affymetrix
santa
clara
ca
usa
form
biotinlabel
crna
fragment
three
independ
biolog
sampl
control
treat
condit
hybridis
affymetrix
genechip
accord
affymetrix
protocol
detail
descript
microarray
analysi
includ
supplementari
method
total
rna
mg
revers
transcrib
use
moloney
murin
leukaemia
viru
revers
transcriptas
promega
madison
wi
usa
accord
manufactur
instruct
vascular
endotheli
growth
factor
vegf
quantifi
rt
pcr
use
sybr
green
univers
master
mix
roch
diagnost
corp
indianapoli
usa
reaction
carri
format
abi
sequenc
detector
perkinelmerappli
biosystem
warrington
cheshir
uk
result
normalis
rrna
amplifi
cdna
mix
express
fold
induct
compar
control
cdna
amplifi
use
follow
primer
pair
aaaatagggcatgcgtgtgaa
tattatacc
aatattccacatatctgttgct
ttgtacccggacagg
attctatg
tgtttggagtgggtttcagaaata
vegf
ca
tgcagattatgcggatcaa
tttgttgtgctgtaggaagct
cat
bax
bclxl
quantif
perform
use
taqman
predevelop
assay
reagent
accord
manufactur
protocol
appli
biosystem
foster
citi
ca
usa
cell
grown
glass
chamber
slide
treat
mm
vehicl
control
h
slide
airdri
fix
methanol
permeabilis
cold
aceton
slide
block
bsa
pb
h
incub
dilut
antibodi
santa
cruz
biotech
santa
cruz
ca
usa
overnight
serial
wash
slide
incub
dilut
fluoresc
label
donkey
antigoat
alexa
fluor
molecular
probe
leiden
netherland
subsequ
propidium
iodid
molecular
probe
dilut
mg
ml
pb
nuclear
counterstain
min
slide
mount
fluoresc
mount
media
dako
carpinteria
ca
usa
imag
zeiss
upright
confoc
microscop
carl
zeiss
germani
cell
seed
densiti
cell
per
well
sixwel
plate
treat
mm
vehicl
control
h
cell
detach
use
versen
min
float
adher
cell
pellet
centrifug
wash
solut
bsa
suspend
pb
perform
fitc
annexin
vpropidium
iodid
label
perform
use
tac
annexin
v
fitc
apoptosi
detect
kit
r
system
abingdon
uk
briefli
cell
resuspend
ml
work
stock
bind
buffer
propidium
iodid
annexin
v
fitc
conjug
incub
dark
min
cell
resuspend
bind
buffer
analysi
facscalibur
flow
cytomet
becton
dickinson
oxford
uk
measur
fluoresc
emiss
nm
channel
nm
channel
four
quadrant
analys
use
cellquest
becton
dickinson
oxford
uk
softwar
allow
quantif
cell
popul
accord
label
characterist
result
verifi
stainingmorpholog
confoc
microscopi
cell
seed
densiti
cell
per
well
sixwel
plate
allow
adher
overnight
cotransfect
mg
sirna
mg
marker
select
transfect
cell
dna
per
well
use
fugen
roch
diagnost
corp
ml
ratio
rna
transfect
reagent
transfect
perform
optimem
ml
per
well
final
concentr
sirna
approxim
nm
neg
control
sirna
scrambl
target
gene
without
sequenc
homolog
known
transcript
verifi
blast
analysi
use
mock
transfect
control
popul
mockand
posit
transfect
cell
subsequ
treat
either
mm
staurosporin
mm
vehicl
control
h
adher
float
cell
pellet
wash
resuspend
ml
pb
molecular
probe
final
concentr
mg
ml
incub
ice
min
dark
sampl
analys
flow
cytometri
use
establish
method
assess
cell
viabil
transfect
cell
select
accord
gfp
fluoresc
vezina
et
al
protocol
approv
ethic
medic
research
committe
beaumont
hospit
dublin
patient
provid
written
inform
consent
colon
cancer
tissu
match
normal
colon
mucosa
obtain
patient
time
surgeri
immedi
place
rnalat
solut
qiagen
gmbh
total
rna
extract
tissu
sampl
addit
patient
newli
diagnos
distal
crc
recruit
separ
protocol
approv
irish
medicin
board
beaumont
hospit
ethic
committe
treatment
day
select
inhibitor
rofecoxib
dose
mg
daili
tumour
sampl
endoscop
day
complet
therapi
place
rnalat
complianc
drug
therapi
monitor
measur
wholeblood
monocyt
activ
previous
describ
panara
et
al
analysi
tumournorm
differ
perform
use
twotail
student
ttest
differ
gene
express
across
time
point
analys
anova
bonferroni
multipl
comparison
test
linear
correl
assess
use
pearson
test
ttest
anova
correl
statist
perform
use
instat
version
graphpad
softwar
la
jolla
ca
usa
examin
regul
apoptosi
human
crc
cell
line
cell
previous
report
express
high
level
abund
pge
gener
sheng
et
al
apoptosi
quantifi
fluoresc
label
fitcconjug
antibodi
annexin
v
propidium
iodid
assess
flow
cytometri
figur
follow
h
treatment
select
inhibitor
mm
signific
decreas
p
cell
viabil
observ
figur
mirror
doubl
proport
cell
popul
gate
earli
apoptosi
phase
annexin
v
posit
propidium
iodid
neg
figur
observ
increas
apoptosi
low
micromolar
dose
prevent
coadministr
exogen
pge
mm
wherea
mark
increas
apoptosi
seen
higher
dose
rescu
similar
effect
note
regard
effect
cell
prolifer
see
supplementari
figur
abil
pge
promot
cell
surviv
confirm
low
micromolar
dose
effect
larg
depend
abil
inhibit
highdens
oligonucleotid
array
identifi
chang
gene
express
cell
confirm
inhibit
caus
apoptot
phenotyp
use
highdens
oligonucleotid
microarray
hdona
examin
earli
global
chang
gene
express
associ
abolit
prostaglandin
product
total
rna
cell
treat
mm
vehicl
control
h
pool
use
probe
affymetrix
genechip
featur
probe
set
differ
human
transcript
three
independ
biolog
replic
assay
condit
ie
vehicl
control
inhibitor
robust
multichip
averag
rma
base
analysi
perform
compar
express
measur
magnitud
chang
express
individu
gene
small
case
reflect
earli
time
point
use
correspond
analysi
coa
rmabas
measur
howev
highlight
signific
global
differ
gene
express
control
treat
sampl
figur
techniqu
similar
princip
compon
analysi
repres
express
hybridis
point
project
threedimension
space
demonstr
consist
alter
transcriptom
cell
treat
inhibitor
express
consist
show
strong
induct
inhibit
novel
serin
threonin
kinas
member
deathassoci
protein
dap
kinas
famili
like
famili
member
implic
control
apoptosi
sanjo
et
al
howev
potenti
function
regul
cell
death
viabil
cancer
explor
date
comparison
express
data
set
anoth
recent
publish
hdona
experi
levitt
et
al
evalu
select
inhibit
breast
cell
line
reveal
cluster
gene
regul
system
see
supplementari
data
tabl
differenti
express
featur
strong
signal
thu
chosen
detail
valid
analysi
differenti
express
confirm
quantit
rtpcr
qrtpcr
templat
cell
induct
express
observ
earli
h
treatment
inhibit
coadministr
pge
figur
induct
express
rel
control
observ
mm
h
p
respons
attenu
coincub
prostaglandin
vs
pge
p
suggest
chang
express
depend
variat
prostaglandin
gener
indirect
immunofluoresc
stain
cell
show
correspond
increas
level
protein
inhibitor
treatment
develop
intens
nuclear
stain
h
posttreat
figur
examin
express
bank
colorect
tumour
sampl
use
total
rna
extract
tumour
normal
mucosa
sampl
freshli
resect
tumour
patient
crc
take
aspirin
nsaid
level
transcript
normalis
rrna
elev
major
tumour
sampl
rel
normal
mucosa
figur
mean
increas
p
express
show
opposit
pattern
rel
suppress
express
tumour
compar
normal
patient
figur
mean
decreas
approxim
p
neg
correl
ratio
express
tumour
rel
normal
note
figur
r
r
p
reflect
invers
relationship
tumournorm
differ
two
gene
across
patient
sampl
observ
suggest
suppress
express
either
directli
indirectli
action
prostaglandin
tumour
sampl
test
hypothesi
five
patient
newli
diagnos
crc
take
aspirin
nsaid
recruit
pilot
studi
endoscop
biopsi
tumour
tissu
obtain
short
cours
day
treatment
inhibitor
rofecoxib
dose
mg
daili
dose
demonstr
select
inhibit
vivo
ehrich
et
al
studi
conduct
withdraw
rofecoxib
manufactur
qrtpcr
demonstr
induct
express
figur
mean
increas
p
tumour
patient
treat
rofecoxib
reflect
chang
seen
inhibit
vitro
express
panel
addit
gene
also
evalu
compar
purpos
figur
although
signific
chang
sever
gene
modul
apoptosi
bax
bclxl
observ
signific
decreas
vegf
express
note
mean
reduct
close
p
proangiogen
factor
previous
link
activ
reduc
vegf
express
observ
anim
model
follow
treatment
rofecoxib
yao
et
al
find
provid
addit
valid
suppress
activ
tumour
patient
final
evalu
phenotyp
activ
cell
system
suspect
express
alreadi
significantli
suppress
cell
given
high
level
express
wherea
cell
show
lower
level
higher
level
express
follow
transient
transfect
cell
commerci
avail
sequenc
valid
sirna
signific
repress
transcript
seen
figur
counteract
effect
low
transfect
effici
maximis
detect
phenotyp
associ
silenc
gfp
express
vector
cotransfect
gatetransfect
silenc
cell
subsequ
assay
quantifi
cell
surviv
use
establish
method
vezina
et
al
percentag
viabl
cell
without
uptak
nonviabl
cell
uptak
calcul
mocktransfect
cell
sirnatransfect
cell
select
gate
gfp
fluoresc
loss
cell
viabil
observ
mocktransfect
cell
follow
treatment
staurosporin
figur
contrast
sirnatransfect
gfpgate
cell
show
loss
cell
viabil
follow
treatment
inhibitor
howev
still
show
signific
loss
viabil
staurosporin
suggest
specif
effect
pathway
involv
action
tradit
nsaid
antineoplast
properti
prolong
use
limit
associ
gastrointestin
side
effect
particularli
risk
gastrointestin
haemorrhag
newgener
coxib
also
shown
promis
chemoprevent
crc
consid
mani
carri
unaccept
risk
thrombot
event
aim
identifi
novel
effector
pathway
oper
downstream
tumour
knowledg
might
allow
futur
select
refin
therapeut
target
number
way
may
promot
cancer
progress
either
effect
cancer
cell
associ
immun
respons
angiogenesi
respons
tumour
evid
express
protect
cell
apoptosi
convers
treatment
crc
cell
select
inhibitor
caus
cellcycl
arrest
growth
inhibit
induct
apoptosi
richter
et
al
sheng
et
al
sheng
et
al
evid
anim
model
hansenpetrik
et
al
human
studi
sinicrop
et
al
suggest
modul
cell
surviv
alter
suscept
apoptosi
equal
import
vivo
howev
precis
mechan
exert
effect
tumour
cell
unclear
enhanc
express
cell
alter
suscept
tumour
necrosi
factorrel
apoptosisinduc
ligand
reduct
membran
death
receptor
tang
et
al
may
also
alter
threshold
intrins
pathway
activ
tang
et
al
overexpress
lead
gener
prostanoid
particularli
pge
signal
variou
ep
receptor
sever
implic
carcinogenesi
watanab
et
al
sonoshita
et
al
mutoh
et
al
pge
stimul
tcfbcateninmedi
gene
transcript
castellon
et
al
shao
et
al
eising
et
al
possibl
activ
receptor
fujino
et
al
import
effect
pge
probabl
also
relat
abil
transactiv
epiderm
growth
factor
receptor
number
distinct
mechan
pai
et
al
shao
et
al
alsalihi
et
al
seem
like
therefor
prostaglandin
gener
crc
cell
exert
activ
singl
mechan
rang
downstream
signal
target
made
use
hdona
identifi
earli
target
gene
downstream
earlier
studi
cell
system
demonstr
abil
regul
gene
express
express
patel
et
al
specif
studi
differenti
gene
express
colon
cancer
cell
use
suppress
subtract
hybridis
differenti
screen
previous
demonstr
alter
express
gene
involv
cell
prolifer
viabil
zhang
duboi
howev
high
nsaid
dose
long
time
point
make
direct
comparison
express
studi
difficult
chose
look
earli
time
point
follow
treatment
highli
select
inhibitor
identifi
crucial
earli
respons
independ
effect
describ
et
al
howev
chose
use
dose
associ
modest
chang
rate
apoptosi
observ
rescu
coincub
pge
belief
studi
subtl
specif
phenotyp
chang
would
yield
signific
find
identifi
show
consist
chang
express
predominantli
nuclear
serin
threonin
kinas
similar
dap
kinas
involv
least
certain
cell
type
initi
apoptosi
sanjo
et
al
unsupervis
hierarch
cluster
express
data
supplementari
figur
select
cluster
gene
show
similar
pattern
upregul
inhibit
cluster
gene
either
known
nuclear
localis
within
cell
bipartit
nuclear
localis
signal
suggest
abil
traffic
nucleu
mani
known
involv
transcript
regul
induct
potenti
apoptosi
prior
express
analys
previous
identifi
nuclear
protein
significantli
overrepres
gene
induc
aspirin
treatment
colon
cancer
cell
hardwick
et
al
mechan
regul
nuclear
traffick
recent
suggest
kuwahara
et
al
confirm
express
colon
cancer
cell
vitro
regul
figur
also
demonstr
vivo
relationship
express
human
crc
figur
implic
modul
tlymphocyt
function
oppos
phenotyp
consequ
activ
cell
patient
sle
markedli
upregul
sustain
express
resist
inactiv
cell
death
xu
et
al
inde
express
shown
mediat
lethal
tcell
activ
brewer
et
al
contrast
overexpress
activ
cell
enhanc
apoptosi
presenc
mao
et
al
studi
mice
target
disrupt
demonstr
protein
import
neg
regul
tcell
activ
rais
threshold
activ
tcell
receptor
mcgargil
et
al
friedrich
et
al
act
import
regul
cell
respons
surviv
schaumburg
et
al
mcgargil
et
al
although
clear
cell
death
celltyp
context
depend
grow
bodi
evid
indic
function
directli
relat
regul
cell
surviv
addit
vivo
evid
transgen
mice
mao
et
al
induct
vitro
varieti
context
cell
type
augment
apoptosi
sanjo
et
al
kuwahara
et
al
mao
et
al
also
show
silenc
express
cell
promot
cell
surviv
abrog
effect
inhibitor
vitro
find
confirm
publish
observ
effect
silenc
rnai
suscept
rat
colon
cancer
cell
uvinduc
apoptosi
kuwahara
et
al
also
recent
observ
may
import
abil
protect
cardiomyocyt
doxorubicininduc
apoptosi
neilan
et
al
suggest
modul
express
may
confin
cancer
may
also
import
posit
effect
cell
viabil
tissu
heal
system
moment
precis
mechan
impact
cell
surviv
unclear
recent
observ
suggest
ribosom
kinas
involv
cellcycl
regul
substrat
mao
et
al
highlight
possibl
involv
regul
cellcycl
dynam
analysi
publicli
avail
express
data
whitfield
et
al
note
form
part
cluster
gene
show
similar
cyclic
chang
express
cellcycl
period
hela
cell
supplementari
figur
supplementari
tabl
interest
degre
overlap
summaris
concis
supplementari
figur
panel
gene
identifi
gene
express
analysi
number
gene
discoveri
studi
examin
effect
cox
inhibitor
iizaka
et
al
levitt
et
al
identif
regul
understand
role
cancer
one
consist
observ
cancer
contribut
vivo
risk
system
metastas
tomozawa
et
al
yao
et
al
fact
like
explain
impair
surviv
observ
individu
whose
tumour
express
sheehan
et
al
previou
observ
effect
dap
kinas
bestcharacteris
member
kinas
famili
belong
cancer
cell
may
provid
unifi
explan
link
abil
dap
kinas
regul
apoptosi
suppress
metastat
potenti
inbal
et
al
plausibl
explan
enhanc
cell
surviv
confer
silenc
provid
resist
variou
form
cell
death
possibl
crucial
anoiki
matrix
detachmentinduc
cell
death
hofmann
et
al
form
cell
death
may
import
decid
viabil
circul
tumour
cell
abil
form
distant
metastas
